ERC Consolidator Grant · 2025
Advancing NANOmedicines to rewire tumoral MYeloid cells for next-generation cancer immunotherapies
Persistent inflammation during tumorigenesis drives myelopoiesis. Consequently, monocytes and granulocytes/neutrophils infiltrate the tumor microenvironment (TME) and differentiate into tumor-associated macrophages or myeloid-derived suppressor cells, creating an immune-suppressive microenvironment that hampers cytotoxic T cell function and limits immune checkpoint inhibitor (ICI) efficacy. ‘Reprogramming’ myeloid cells to adopt pro-inflammatory phenotypes is promising to restore immune function and enhance ICI responses. Lipid nanoparticles (LNPs) have emerged as a delivery platform for nucleic acids, as demonstrated by the mRNA-LNP COVID vaccines. Pioneering studies revealed that myeloid…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.